Clinical trialNCT00574951TerminatedPhase 2Interventional

AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

SponsorGynecologic Oncology GroupEnrollment23Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cavity Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: AMG 706 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well AMG 706 works in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Russell J. Schilder, MD
Fox Chase Cancer Center
Study ChairKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Providence Saint Joseph Medical Center - Burbank
Burbank, California, United States
George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
New Britain, Connecticut, United States
Rush University Medical Center
Chicago, Illinois, United States
University of Illinois Cancer Center
Chicago, Illinois, United States
Hinsdale Hematology Oncology Associates
Hinsdale, Illinois, United States
St. Vincent Indianapolis Hospital
Indianapolis, Indiana, United States
Hulston Cancer Center at Cox Medical Center South
Springfield, Missouri, United States
St. John'S Regional Health Center
Springfield, Missouri, United States
Cancer Institute of New Jersey at Cooper - Voorhees
Voorhees Township, New Jersey, United States
Blumenthal Cancer Center at Carolinas Medical Center
Charlotte, North Carolina, United States
Case Comprehensive Cancer Center
Cleveland, Ohio, United States
Mount Carmel Health - West Hospital
Columbus, Ohio, United States
Lake/university Ireland Cancer Center
Mentor, Ohio, United States
Oklahoma University Cancer Institute
Oklahoma City, Oklahoma, United States
Rosenfeld Cancer Center at Abington Memorial Hospital
Abington, Pennsylvania, United States
Fox Chase Cancer Center - Philadelphia
Philadelphia, Pennsylvania, United States
Mcglinn Family Regional Cancer Center at Reading Hospital and Medical Center
Reading, Pennsylvania, United States
Harrington Cancer Center
Amarillo, Texas, United States
University of Virginia Cancer Center
Charlottesville, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Motesanib diphosphate

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Dec 2007
Primary completion: 31 Jul 2013
Completion: —
Last update posted: 11 Jan 2018
Registered enrollment: 23
Registry id: NCT00574951

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.